Discover the portfolio strategy of this venture fund for investing in life science companies

A snapshot of our investment portfolio

The Novartis Venture Fund currently invests in over 40 life science companies across North America and Europe with approximately USD 750 million under management.

Our investment strategy

We specialize in investments ranging from USD 5-10 million, primarily focusing on Seed and Series A stage companies. However, we remain open to exploring later-stage opportunities as well. We allocate up to USD 25 million for each company we engage with, allowing us to provide substantial support across various growth phases.

We work with companies at all stages of development

The Novartis Venture Fund makes equity investments in biotechnology and biopharma life science companies. Whether your company is at seed stage or in later-stage development, we prefer to play an active role by taking a seat on the board.

Explore the NVF portfolio

World map highlighting North America and Europe.

We invest in a wide array of life science companies in North America
and Europe from our offices in Basel, Switzerland and Cambridge, MA, USA.

Our Portfolio Investments

Select a company to learn more

The Novartis Venture Fund has enjoyed great success

Our team members have strong backgrounds in science and business development, and achieved great success investing in drug development across a broad range of therapeutic areas and drug modalities.

Learn more about our successes

We fund life science innovations with the potential to make real clinical impact

With a focus on those companies developing novel therapeutics and platforms in the biotechnology and biopharma space, the NVF ambition is to address unmet patient needs.

Find out more about our fund focus

Novartis Venture Fund Portfolio